CN104805121B - 抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 - Google Patents
抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 Download PDFInfo
- Publication number
- CN104805121B CN104805121B CN201510043628.4A CN201510043628A CN104805121B CN 104805121 B CN104805121 B CN 104805121B CN 201510043628 A CN201510043628 A CN 201510043628A CN 104805121 B CN104805121 B CN 104805121B
- Authority
- CN
- China
- Prior art keywords
- cell
- antibody
- expression
- segment
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 37
- 102000014914 Carrier Proteins Human genes 0.000 title abstract description 74
- 108091008324 binding proteins Proteins 0.000 title abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 190
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 80
- 210000004027 cell Anatomy 0.000 claims description 626
- 230000014509 gene expression Effects 0.000 claims description 299
- 108090000623 proteins and genes Proteins 0.000 claims description 150
- 239000000427 antigen Substances 0.000 claims description 138
- 108091007433 antigens Proteins 0.000 claims description 138
- 102000036639 antigens Human genes 0.000 claims description 138
- 241001430294 unidentified retrovirus Species 0.000 claims description 137
- 230000001177 retroviral effect Effects 0.000 claims description 113
- 238000010361 transduction Methods 0.000 claims description 103
- 230000026683 transduction Effects 0.000 claims description 103
- 238000010839 reverse transcription Methods 0.000 claims description 78
- 210000004698 lymphocyte Anatomy 0.000 claims description 59
- 230000006798 recombination Effects 0.000 claims description 57
- 238000005215 recombination Methods 0.000 claims description 56
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 55
- 239000005090 green fluorescent protein Substances 0.000 claims description 41
- 230000027455 binding Effects 0.000 claims description 40
- 239000002243 precursor Substances 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 37
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 36
- 238000012216 screening Methods 0.000 claims description 32
- 210000001185 bone marrow Anatomy 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 239000003550 marker Substances 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 17
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 16
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 15
- 101710166261 B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 12
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 claims description 6
- 230000010354 integration Effects 0.000 claims description 6
- 210000002751 lymph Anatomy 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 108010054624 red fluorescent protein Proteins 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 229940127121 immunoconjugate Drugs 0.000 claims description 3
- 231100000219 mutagenic Toxicity 0.000 claims description 3
- 230000003505 mutagenic effect Effects 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 239000002458 cell surface marker Substances 0.000 claims description 2
- 241000270322 Lepidosauria Species 0.000 claims 1
- 238000004091 panning Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 68
- 238000011065 in-situ storage Methods 0.000 abstract description 18
- 238000000338 in vitro Methods 0.000 abstract description 15
- 230000009870 specific binding Effects 0.000 abstract description 5
- 239000012634 fragment Substances 0.000 description 90
- 108060003951 Immunoglobulin Proteins 0.000 description 88
- 102000018358 immunoglobulin Human genes 0.000 description 88
- 210000003719 b-lymphocyte Anatomy 0.000 description 72
- 230000002068 genetic effect Effects 0.000 description 69
- 102000003812 Interleukin-15 Human genes 0.000 description 61
- 108090000172 Interleukin-15 Proteins 0.000 description 61
- 241000699666 Mus <mouse, genus> Species 0.000 description 60
- 239000013604 expression vector Substances 0.000 description 54
- 108091008146 restriction endonucleases Proteins 0.000 description 54
- 230000009257 reactivity Effects 0.000 description 49
- 230000008569 process Effects 0.000 description 41
- 238000010367 cloning Methods 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 38
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 37
- 241000700605 Viruses Species 0.000 description 36
- 239000013615 primer Substances 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 34
- 230000035772 mutation Effects 0.000 description 33
- 230000000392 somatic effect Effects 0.000 description 33
- 238000004043 dyeing Methods 0.000 description 30
- 238000005516 engineering process Methods 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 29
- 238000012546 transfer Methods 0.000 description 28
- 238000012408 PCR amplification Methods 0.000 description 26
- 239000013641 positive control Substances 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000001404 mediated effect Effects 0.000 description 21
- 108090000193 Interleukin-1 beta Proteins 0.000 description 20
- 102000003777 Interleukin-1 beta Human genes 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 239000003623 enhancer Substances 0.000 description 19
- 230000002441 reversible effect Effects 0.000 description 19
- 238000011144 upstream manufacturing Methods 0.000 description 19
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 18
- 241000894007 species Species 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 230000008859 change Effects 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000002823 phage display Methods 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 14
- 206010069754 Acquired gene mutation Diseases 0.000 description 13
- 241000283984 Rodentia Species 0.000 description 13
- 230000003321 amplification Effects 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 238000004806 packaging method and process Methods 0.000 description 13
- 230000008707 rearrangement Effects 0.000 description 13
- 230000037439 somatic mutation Effects 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000013011 mating Effects 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 230000008521 reorganization Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 11
- 239000000969 carrier Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000002703 mutagenesis Methods 0.000 description 11
- 231100000350 mutagenesis Toxicity 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 10
- 102000001183 RAG-1 Human genes 0.000 description 10
- 108060006897 RAG1 Proteins 0.000 description 10
- 230000007071 enzymatic hydrolysis Effects 0.000 description 10
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 9
- 108700008625 Reporter Genes Proteins 0.000 description 9
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 241000714175 Abelson murine leukemia virus Species 0.000 description 8
- 102100026846 Cytidine deaminase Human genes 0.000 description 8
- 108010031325 Cytidine deaminase Proteins 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 229950010131 puromycin Drugs 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241001515965 unidentified phage Species 0.000 description 8
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 101000755751 Mus musculus Single-stranded DNA cytosine deaminase Proteins 0.000 description 7
- 108020005038 Terminator Codon Proteins 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 7
- 230000012846 protein folding Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 238000001712 DNA sequencing Methods 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 6
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 6
- 108010006519 Molecular Chaperones Proteins 0.000 description 6
- 241000714177 Murine leukemia virus Species 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 6
- 229940097277 hygromycin b Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 210000001586 pre-b-lymphocyte Anatomy 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 5
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 5
- 102000005431 Molecular Chaperones Human genes 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004873 anchoring Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 102000057593 human F8 Human genes 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229940047431 recombinate Drugs 0.000 description 5
- 239000012925 reference material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 101150097493 D gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 3
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 3
- 108091029795 Intergenic region Proteins 0.000 description 3
- 101150008942 J gene Proteins 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000012137 double-staining Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000002702 ribosome display Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 2
- BQIMPGFMMOZASS-CLZZGJSISA-N (6r,7r)-7-amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 BQIMPGFMMOZASS-CLZZGJSISA-N 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000037189 immune system physiology Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000012128 staining reagent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000029305 taxis Effects 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- 108010088237 ATCGAT-specific type II deoxyribonucleases Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010013534 Auxilins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101000618318 Enterobacteria phage T4 Uncharacterized 8.2 kDa protein in Gp46-Gp47 intergenic region Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 244000290594 Ficus sycomorus Species 0.000 description 1
- 229930195503 Fortimicin Natural products 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101000823949 Homo sapiens Serine palmitoyltransferase 2 Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100020744 Immunoglobulin iota chain Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101100340196 Mus musculus Il27ra gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 description 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 description 1
- 101150099412 ORF V gene Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010016231 Pre-B Cell Receptors Proteins 0.000 description 1
- 102000000434 Pre-B Cell Receptors Human genes 0.000 description 1
- 102100023922 Putative tyrosine-protein phosphatase auxilin Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100022059 Serine palmitoyltransferase 2 Human genes 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 101710193562 Small outer capsid protein Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 1
- 101710199973 Tail tube protein Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000007720 allelic exclusion Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- BIDUPMYXGFNAEJ-APGVDKLISA-N astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000027174 regulation of B cell differentiation Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- -1 threonine amino acid Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
Abstract
Description
Claims (24)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08004096.7 | 2008-03-05 | ||
EP20080004096 EP2098536A1 (en) | 2008-03-05 | 2008-03-05 | Isolation and identification of antigen- or ligand-specific binding proteins |
US12588608P | 2008-04-29 | 2008-04-29 | |
US61/125886 | 2008-04-29 | ||
CN200980107592.4A CN101970482B (zh) | 2008-03-05 | 2009-03-04 | 抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980107592.4A Division CN101970482B (zh) | 2008-03-05 | 2009-03-04 | 抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104805121A CN104805121A (zh) | 2015-07-29 |
CN104805121B true CN104805121B (zh) | 2018-12-14 |
Family
ID=39764879
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510043628.4A Active CN104805121B (zh) | 2008-03-05 | 2009-03-04 | 抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 |
CN200980107592.4A Expired - Fee Related CN101970482B (zh) | 2008-03-05 | 2009-03-04 | 抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980107592.4A Expired - Fee Related CN101970482B (zh) | 2008-03-05 | 2009-03-04 | 抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 |
Country Status (19)
Country | Link |
---|---|
US (4) | US8748353B2 (zh) |
EP (3) | EP2098536A1 (zh) |
JP (2) | JP5707650B2 (zh) |
KR (1) | KR101764426B1 (zh) |
CN (2) | CN104805121B (zh) |
AU (1) | AU2009221239B2 (zh) |
BR (1) | BRPI0907864B1 (zh) |
CA (1) | CA2715341C (zh) |
DK (1) | DK2098537T3 (zh) |
ES (1) | ES2528753T3 (zh) |
HK (2) | HK1149280A1 (zh) |
IL (2) | IL207573A (zh) |
MX (2) | MX2010009585A (zh) |
NZ (1) | NZ587512A (zh) |
PT (1) | PT2098537E (zh) |
SG (2) | SG188841A1 (zh) |
SI (1) | SI2098537T1 (zh) |
WO (1) | WO2009109368A1 (zh) |
ZA (1) | ZA201005882B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
CA2757178C (en) * | 2009-04-03 | 2020-05-19 | Medical Research Council | Mutants of activation-induced cytidine deaminase (aid) and methods of use |
WO2012158948A1 (en) | 2011-05-17 | 2012-11-22 | The Rockefeller University | Human immunodeficiency virus neutralizing antibodies adn methods of use thereof |
KR20140107295A (ko) * | 2011-12-22 | 2014-09-04 | 에프. 호프만-라 로슈 아게 | 진핵 세포용 전장 항체 표시 시스템 및 그것의 용도 |
ES2529419T3 (es) * | 2012-01-12 | 2015-02-19 | Adnagen Gmbh | Método para la cuantificación, caracterización genética cualitativa y caracterización de la expresión génica de células predeterminadas |
DK2692865T3 (en) | 2012-07-30 | 2015-02-16 | Nbe Therapeutics Llc | Transponeringsmedieret identification of specific binding proteins, or functional |
TWI619727B (zh) * | 2013-02-27 | 2018-04-01 | 中央研究院 | 抗體之原位親和力成熟作用 |
JP6962563B2 (ja) * | 2015-05-12 | 2021-11-05 | 株式会社オンチップ・バイオテクノロジーズ | 単一粒子解析方法およびその解析のためのシステム |
GB201603372D0 (en) * | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Cell |
JP2023510963A (ja) * | 2020-01-21 | 2023-03-15 | シンテゴ コーポレイション | 細胞のトランスフェクションおよび細胞のクローン集団の生成のためのデバイスおよび方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1041143A2 (en) * | 1995-06-02 | 2000-10-04 | M & E Biotech A/S | A method for identification of biologically active peptides and nucleic acids |
CN1408874A (zh) * | 2001-09-25 | 2003-04-09 | 韩泽广 | 原核细胞体内抗体文库构建、抗体的筛选和优化及用途 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4713332A (en) | 1984-01-13 | 1987-12-15 | The Ontario Cancer Institute | T cell specific CDNA clone |
WO1985003947A1 (en) | 1984-03-01 | 1985-09-12 | The Board Of Trustees Of The Leland Stanford Jr. U | T-cell receptor-specific for antigen polypeptides and related polynucleotides |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE144791T1 (de) | 1987-06-23 | 1996-11-15 | Univ Leland Stanford Junior | Innerhalb des alpha-locus gelegenes t-zell- rezeptor-gen und dna-konstruktionen |
US6544771B1 (en) | 1987-12-11 | 2003-04-08 | Cell Genesys, Inc. | Retroviral gene therapy vectors and therapeutic methods based thereon |
JP2981486B2 (ja) | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | 哺乳動物の免疫系研究方法 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
AU5675790A (en) | 1989-05-09 | 1990-11-29 | Cetus Corporation | Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria |
US6969586B1 (en) | 1989-05-16 | 2005-11-29 | Scripps Research Institute | Method for tapping the immunological repertoire |
US6291160B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6680192B1 (en) | 1989-05-16 | 2004-01-20 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5871974A (en) | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
US5753432A (en) | 1990-10-19 | 1998-05-19 | Board Of Trustees Of The University Of Illinois | Genes and genetic elements associated with control of neoplastic transformation in mammalian cells |
ATE243747T1 (de) | 1991-07-15 | 2003-07-15 | Wellcome Found | Herstellung von antikörpern |
US6319707B1 (en) | 1991-08-12 | 2001-11-20 | Fred Hutchinson Cancer Research Center Board Regents Of The University Of Washington | Cap-independent multicistronic retroviral vectors |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
US6051427A (en) | 1993-06-11 | 2000-04-18 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US6506604B2 (en) | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
KR970010603B1 (ko) | 1993-09-17 | 1997-06-28 | 신원철 | 신규 항진균성 항생물질과 이를 생산하는 신규 바실러스 속(Bacillus sp.) 미생물 및 이를 이용한 신규 항진균성 항생물질의 제조방법 |
DE4406512C1 (de) | 1994-02-28 | 1995-02-16 | Gsf Forschungszentrum Umwelt | Integrationsvektoren zur Herstellung von Genen, die rekombinante Antikörper codieren |
US20010053523A1 (en) | 1995-06-02 | 2001-12-20 | M&E Biotech A/S. | Method for identification of biologically active peptides and nucleic acids |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
EP0934953A2 (en) | 1997-12-03 | 1999-08-11 | Boehringer Mannheim Corporation | Complex specific antibodies, method of preparation and uses thereof |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
DE19816129A1 (de) | 1998-04-09 | 1999-10-14 | Dolores Schendel | T-Zellrezeptor-Expressionskassette |
CA2675802A1 (en) | 1998-10-09 | 2000-04-20 | Medical Research Council | Use of an immunoglobulin-producing cell line to gererate diversity in a gene or gene product |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
EP1188825A1 (en) | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
EP1830190A3 (en) | 2000-11-17 | 2008-07-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
US20050196755A1 (en) | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
JP4359503B2 (ja) | 2001-08-23 | 2009-11-04 | ゲンマブ エー/エス | インターロイキン15(il−15)に特異的なヒト抗体 |
EP1438400B1 (en) | 2001-10-01 | 2009-06-17 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
EP1456383B1 (en) * | 2001-12-21 | 2014-03-12 | Medigene AG | A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
CA2471392A1 (en) * | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
US20040038304A1 (en) | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
DK1506288T3 (da) | 2002-05-10 | 2013-07-22 | Medical Res Council | Aktiveringsinduceret deaminase (aid) |
ATE386810T1 (de) | 2002-06-14 | 2008-03-15 | Dyax Corp | Rekombination von nukleinsäurebibliotheksmitgliedern |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
AU2003276403B2 (en) | 2002-11-09 | 2010-04-15 | Adaptimmune Limited | T cell receptor display |
ATE536548T1 (de) | 2002-11-14 | 2011-12-15 | Vivalis | Mikrowell-array-chip zum nachweis eines antigenspezifischen lymphozyten, verfahren zum nachweis eines antigenspezifischen lymphozyten und verfahren zur klonierung eines antigenrezeptorgens eines antigenspezifischen lymphozyten |
EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
EP1784506B1 (en) | 2004-07-21 | 2010-08-25 | Dana-Farber Cancer Institute, Inc. | Lentiviral vectors and uses thereof |
GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
PL2327763T3 (pl) | 2005-08-05 | 2018-08-31 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | Generowanie komórek T specyficznych względem antygenu |
KR101030612B1 (ko) | 2005-10-21 | 2011-04-20 | 에프. 호프만-라 로슈 아게 | 폴리펩타이드의 재조합 발현 방법 |
EP1979378B1 (en) | 2005-12-20 | 2012-07-25 | MorphoSys AG | Novel collection of hcdr3 regions and uses therefor |
WO2007137616A1 (en) | 2006-05-30 | 2007-12-06 | Millegen | Highly diversified antibody libraries |
EP1975239A1 (en) | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
EP1921142A1 (en) | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
EP2126105A4 (en) | 2007-02-20 | 2010-11-03 | Anaptysbio Inc | SOMATIC HYPERPERMUTATION SYSTEMS |
JP5941616B2 (ja) | 2007-05-25 | 2016-06-29 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組み換えポリクローナルタンパク質を製造する方法 |
EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
US8637435B2 (en) | 2007-11-16 | 2014-01-28 | Merck Sharp & Dohme Corp. | Eukaryotic cell display systems |
FR2924440B1 (fr) | 2007-12-04 | 2015-01-09 | Pf Medicament | Nouveau procede de generation et de criblage d'une banque d'anticorps |
EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
CA2736277C (en) | 2008-09-10 | 2016-06-21 | Philochem Ag | Display library for antibody selection |
CN102282256B (zh) | 2008-12-05 | 2014-09-17 | 凯奥目生物科学株式会社 | 针对在细胞表面表达的蛋白质的抗体制作方法 |
MX2015000979A (es) | 2012-07-27 | 2015-11-23 | Univ Illinois | Ingenieria de receptores de celulas t. |
-
2008
- 2008-03-05 EP EP20080004096 patent/EP2098536A1/en not_active Ceased
-
2009
- 2009-03-04 US US12/397,957 patent/US8748353B2/en active Active
- 2009-03-04 SG SG2013015805A patent/SG188841A1/en unknown
- 2009-03-04 ES ES09003076.8T patent/ES2528753T3/es active Active
- 2009-03-04 NZ NZ587512A patent/NZ587512A/en not_active IP Right Cessation
- 2009-03-04 DK DK09003076.8T patent/DK2098537T3/en active
- 2009-03-04 CA CA2715341A patent/CA2715341C/en not_active Expired - Fee Related
- 2009-03-04 PT PT09003076T patent/PT2098537E/pt unknown
- 2009-03-04 JP JP2010549052A patent/JP5707650B2/ja not_active Expired - Fee Related
- 2009-03-04 CN CN201510043628.4A patent/CN104805121B/zh active Active
- 2009-03-04 WO PCT/EP2009/001525 patent/WO2009109368A1/en active Application Filing
- 2009-03-04 CN CN200980107592.4A patent/CN101970482B/zh not_active Expired - Fee Related
- 2009-03-04 AU AU2009221239A patent/AU2009221239B2/en not_active Ceased
- 2009-03-04 BR BRPI0907864-9A patent/BRPI0907864B1/pt not_active IP Right Cessation
- 2009-03-04 EP EP12163003.2A patent/EP2489674B1/en active Active
- 2009-03-04 MX MX2010009585A patent/MX2010009585A/es active IP Right Grant
- 2009-03-04 EP EP20090003076 patent/EP2098537B1/en active Active
- 2009-03-04 KR KR1020107020411A patent/KR101764426B1/ko active IP Right Grant
- 2009-03-04 SG SG10201503155VA patent/SG10201503155VA/en unknown
- 2009-03-04 MX MX2014015500A patent/MX355993B/es unknown
- 2009-03-04 SI SI200931117T patent/SI2098537T1/sl unknown
-
2010
- 2010-08-12 IL IL207573A patent/IL207573A/en active IP Right Grant
- 2010-08-17 ZA ZA2010/05882A patent/ZA201005882B/en unknown
-
2011
- 2011-04-11 HK HK11103625.4A patent/HK1149280A1/zh not_active IP Right Cessation
- 2011-09-29 US US13/248,487 patent/US8716194B2/en active Active
-
2014
- 2014-04-15 US US14/252,809 patent/US9593327B2/en active Active
- 2014-12-11 JP JP2014250886A patent/JP6019540B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-03 IL IL241093A patent/IL241093A0/en unknown
-
2016
- 2016-01-27 HK HK16100876.1A patent/HK1213012A1/zh unknown
-
2017
- 2017-01-27 US US15/418,192 patent/US10502745B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1041143A2 (en) * | 1995-06-02 | 2000-10-04 | M & E Biotech A/S | A method for identification of biologically active peptides and nucleic acids |
CN1408874A (zh) * | 2001-09-25 | 2003-04-09 | 韩泽广 | 原核细胞体内抗体文库构建、抗体的筛选和优化及用途 |
Non-Patent Citations (4)
Title |
---|
IL-4做为B淋巴细胞存活因子的研究;于士广等;《免疫学杂志》;19951203;第11卷(第2期);第87-90页 * |
Precursor B Cells Showing H Chain Allelic Inclusion Display Allelic Exclusion at the Level of Pre-B Cell Receptor Surface Expression;Edwin ten Boekel et al;《Immunity》;19980228;第8卷;第199-207页 * |
the expression of Vpre-b/λ5 surrogate light chain in early bone marrow precursor B cells of normal and B cell-deficient mutant mice;Hajime Karasuyama et al;《cell》;19940408;第77卷;第133-143页 * |
V(D)J recombination of chromosomally integrated, wild-type deletional and inversional substrates occur at similar frequencies with no preference for orientation;Maureen Shuh et al;《Immunology Letters》;20041020;第97卷;第69-80页 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104805121B (zh) | 抗原特异性结合蛋白或配体特异性结合蛋白的鉴定 | |
JP6043431B2 (ja) | 特異的な結合タンパク質または機能性タンパク質の遺伝子転位を利用した同定 | |
CN105452546B (zh) | 与真核细胞调节剂相关的方法和组合物 | |
CN102449149A (zh) | 集合及其使用方法 | |
CN107090031A (zh) | 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法 | |
CN102282266A (zh) | 高复杂度哺乳动物展示文库及其筛选方法 | |
CN109906272A (zh) | 产生人抗体的非人动物和使用该非人动物的人抗体制作方法 | |
CN104870646A (zh) | 一种新颖的细胞系筛选方法 | |
CN105051211B (zh) | 抗体的原位亲和力成熟作用 | |
CN100383244C (zh) | 用于生产重组多克隆蛋白质的方法 | |
AU2014274595B2 (en) | Identification of antigen- or ligand-specific binding proteins | |
BR112015000836B1 (pt) | Método para identificar um polipeptídeo tendo uma funcionalidade ou especificidade de ligação desejadas, biblioteca de moléculas de polinucleotídeo, método para gerar uma biblioteca de polinucleotídeos e método para gerar uma população de células hospedeiras |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1213012 Country of ref document: HK |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170411 Address after: Massachusetts, USA Applicant after: Etam news company Address before: Basel Applicant before: Antibody AG. 4 |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1213012 Country of ref document: HK |